Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores).

导出 OA

翻译打印收藏纠错

第一作者： Judith Isabel,Schimpf

第一单位： Division of Nephrology and Clinical Immunology, RWTH Aachen University, Pauwelsstr. 30, 52074, Aachen, Germany.

作者： Judith Isabel,Schimpf ^[1] ; Till,Klein ^[2] ; Christina,Fitzner ^[3] ; Frank,Eitner ^[4] ; Stefan,Porubsky ^[5] ; Ralf-Dieter,Hilgers ^[3] ; Jürgen,Floege ^[1] ; Hermann-Josef,Groene ^[6] ; Thomas,Rauen ^[7]

作者单位： Division of Nephrology and Clinical Immunology, RWTH Aachen University, Pauwelsstr. 30, 52074, Aachen, Germany. ^[1] Division of Nephrology and Clinical Immunology, RWTH Aachen University, Pauwelsstr. 30, 52074, Aachen, Germany.;Department of Intensive Care, RWTH Aachen University, Aachen, Germany. ^[2] Department of Medical Statistics, RWTH Aachen University, Aachen, Germany. ^[3] Bayer AG, Wuppertal, Germany. ^[4] Cellular and Molecular Pathology, German Cancer Research Center, Heidelberg, Germany.;Institute of Pathology, University Medical Centre Mannheim, Mannheim, Germany. ^[5] Cellular and Molecular Pathology, German Cancer Research Center, Heidelberg, Germany. ^[6] Division of Nephrology and Clinical Immunology, RWTH Aachen University, Pauwelsstr. 30, 52074, Aachen, Germany. trauen@ukaachen.de. ^[7]

关键词 IgA nephropathy IgAN MEST-C Oxford classification STOP-IgAN